Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.

Keith T. Flaherty,Michael A. Davies,Jean-Jacques Grob,Georgina V. Long,Paul D. Nathan,Antoni Ribas,Caroline Robert,Dirk Schadendorf,Dennie T. Frederick,Marc R. Hammond,Judit Jané-Valbuena,Xinmeng Jasmine Mu,Matthew Squires,Savina Jaeger,Stephen R. Lane,Bijoyesh Mookerjee,Levi A. Garraway

Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.

2016

Keith T. Flaherty
Michael A. Davies
Jean-Jacques Grob
Georgina V. Long
Paul D. Nathan
Antoni Ribas
Caroline Robert
Dirk Schadendorf
Dennie T. Frederick
Marc R. Hammond
Judit Jané-Valbuena
Xinmeng Jasmine Mu
Matthew Squires
Savina Jaeger
Stephen R. Lane
Bijoyesh Mookerjee
Levi A. Garraway

9502Background: Previous analysis of COMBI-d (NCT01584648) showed that D+T compared with D monotherapy improved ORR (69% [95% CI, 62%-75%] vs 53% [95% CI, 46%-60%]; P = 0.0014), reduced risk of pro...

Keywords:

Melanoma
Pathology
Dabrafenib
Phases of clinical research
Oncology
BRAF V600E
Mutant
Trametinib
Medicine
Internal medicine
cutaneous melanoma
in patient
reduced risk

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations